Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Phase II Trial of Gemcitabine, Avelumab and Carboplatin vs. No Neoadjuvant Therapy Preceding Surgery for Cisplatin-Ineligible Muscle-Invasive Urothelial Carcinoma: SWOG GAP TRIAL

NCT04871529 is registered in ClinicalTrials.gov with SWOG Cancer Research Network as lead sponsor.

NCT NCT04871529
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04871529 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Phase II Trial of Gemcitabine, Avelumab and Carboplatin vs. No Neoadjuvant Therapy Preceding Surgery for Cisplatin-Ineligible Muscle-Invasive Urothelial Carcinoma: SWOG GAP TRIAL
Lead sponsor
SWOG Cancer Research Network
Phase
Phase 2
Overall status
Terminated
Start date
August 10, 2022
Completion date
June 26, 2024
Enrollment
6 (actual)
Sites
92

Conditions

As the registry lists them; a condition with its own page is linked.

bladder carcinoma infiltrating the muscle of the bladder wall, infiltrating renal pelvis and ureter urothelial carcinoma, stage ii bladder cancer ajcc v8